- Home
- JMSB vs ZNTL Comparison
JMSB vs ZNTL Comparison
Compare JMSB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | ZNTL |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.2M | 289.0M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JMSB | ZNTL |
|---|---|---|
| Price | $22.09 | $4.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $23.00 | $6.60 |
| AVG Volume (30 Days) | 59.6K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 24.17 | 18.03 |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.09 | N/A |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | $51.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.02 | $1.21 |
| 52 Week High | $22.78 | $6.95 |
Technical Indicators
Market Signals| Indicator | JMSB | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 63.03 |
| Support Level | $20.57 | $3.53 |
| Resistance Level | $22.35 | $6.95 |
| Average True Range (ATR) | 0.73 | 0.39 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 53.67 | 75.91 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.